Leadiant Biosciences, Inc

Employee size

51-200

Organization type

Privately Held

Headquarters

Rockville, MD

From its Rockville base, Leadiant Biosciences develops and distributes prescription therapies for people living with rare diseases. The private U.S. pharmaceutical company draws on a longstanding heritage in orphan-drug development, becoming the fourth company in the world to receive a U.S. Orphan Drug Designation in 1984. Its research teams work with physicians, researchers, academic institutions and biotechnology organizations, while patient-support programs provide education and resources beyond the medicine itself.

• Rocket Pharmaceuticals, IncRocket Pharmaceuticals is a Cranbury, New Jersey biotechnology company developing and manufacturing genetic therapies intended to address the root causes of rare diseases. Its integrated research and manufacturing operation includes roughly 30,000 square feet of laboratories and a 103,720-square-foot facility built in 2022, with programs spanning inherited cardiovascular and blood disorders. Rocket’s first FDA-approved gene therapy, KRESLADI, treats severe leukocyte adhesion deficiency-I.NEW YORK, NY
• Nobelpharma America, LLCEstablished in Bethesda in 2019 as the first global subsidiary of a Japanese pharmaceutical company founded in Tokyo in 2003, Nobelpharma America develops and brings medicines and medical devices to U.S. patients with rare or underserved conditions. Its purpose is to pursue treatments that larger companies may overlook because few patients are affected or existing options are limited. The company works with worldwide experts to move essential therapies from development toward patients, caregivers, and health care providers.BETHESDA, MD
• Ranedis PharmaceuticalsRanedis Pharmaceuticals is a private biopharmaceutical company focused on the treatment and management of rare and neglected diseases, with initial efforts focused on lysosomal storage diseases.MEDIA, PA
• Rise Therapeutics, LLCRockville-based Rise Therapeutics develops oral immunotherapies that use synthetic biology to target dendritic cells and recalibrate immune responses in autoimmune disease and cancer. The clinical-stage company pairs its proprietary oral delivery platform with in-house clinical GMP manufacturing, taking candidates from discovery through human clinical validation. Its pipeline includes oral programs for ulcerative colitis, rheumatoid arthritis, and cancer.POTOMAC, MD